No Data
AstraZeneca PLC Stock Flat Friday
AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.
AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.
AstraZeneca Call Volume Above Normal and Directionally Bullish
Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6
AstraZeneca Announces Share Capital and Voting Rights Update
AstraZeneca (AZN.US) "Osimertinib" has been approved for a new indication in China.
On January 2nd, the National Medical Products Administration website showed that AstraZeneca (AZN.US)'s application for the new indication of Osimertinib has officially been approved.
loading...
NoobGirl : bro is this real that roaring kitty gonna come?